OncLive.com

Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.

[OncLive.com @OncLive]

Celebrate the leaders making a difference in cancer care! 🌟

Hear from past inductee @szusmani and nominate an outstanding colleague for Giants of Cancer Care. Let’s recognize excellence in oncology! Nominations close November 15. https://t.co/EQXRnBT2LT #GiantsCC27

[OncLive.com @OncLive]

Can ctDNA monitoring beat scans in metastatic uveal melanoma? Alexander N. Shoushtari, MD, says not yet, and lays out what trials must prove before ctDNA can drive treatment decisions.

Watch now in the OncLive® supplement: https://t.co/IfgaSVXnWv

@MSKCancerCenter #melsm #ctDNA #UvealMelanoma

[OncLive.com @OncLive]

Could a liquid TKI ease the dosing and adherence challenges that have long shaped GIST care? Jonathan Trent, MD, PhD, weighs the potential gains in flexibility and quality of life in a new OncLive® supplement.

Explore the supplement: https://t.co/v5BfNX0CJB

@SylvesterCancer #scmsm #GIST

[OncLive.com @OncLive]

BTG Breast Live Stream- OncLive https://t.co/ZSO3iFMeIf

[OncLive.com @OncLive]

🌟 @DrPatrickBorgen, of @MaimoHealth, stopped by during BTG Breast to share a surgeon's perspective on HER2+ breast cancer discussions from the meeting. Thanks, Dr Borgen! #bcsm #oncology

See our site for more ➡️: https://t.co/XonIlWO5yz

[OncLive.com @OncLive]

🏙️ It's Day 2 of Bridging the Gaps in Breast Cancer! The stage is all set to host more discussions about evolutions in breast oncology. #bcsm #oncology

Follow along here and on our site for more exclusive expert insights ➡️: https://t.co/XonIlWO5yz

[OncLive.com @OncLive]

🗓️ October brought tons of breast cancer news, like an FDA approval for HER2+ disease, a wave of phase 3 data from #ESMO2026, and expert perspectives on oral SERDs, survivorship, and brain metastases. #bcsm #oncology

Sign up to read the full recap ➡️! https://t.co/b6hpQwaiQe

[OncLive.com @OncLive]

WATCH 📹: @KelseyNatsuhara, of @UCSFCancer, highlights the gaps in antibody-drug conjugate research and literature that are being discussed at the Bridging the Gaps in Breast Cancer meeting! #bcsm #oncology

See our site for more from the meeting ➡️! https://t.co/XonIlWODo7

[OncLive.com @OncLive]

WATCH: @SaraNunneryMD, of @TNOncology, discusses genomic testing, ovarian function suppression, and toxicity management in hormone receptor–positive breast cancer. #bcsm #oncology

Full video: https://t.co/DV8nZZUKUD

[OncLive.com @OncLive]

⚛️ Data from the phase 2/3 COMPANION-002 trial showed a promising new strategy for patients with biliary tract cancer utilizing tovecimig plus paclitaxel

Read more here 📈: https://t.co/pUPtfem35G

#oncology

[OncLive.com @OncLive]

🫁 The addition of LK101, a personalized neoantigen dendritic cell vaccine, to first-line maintenance with tislelizumab in locally advanced or metastatic NSCLC, supporting further, earlier evaluation of the combination

Read more here 📰: https://t.co/7koHTyU9uW

#oncology #lcsm

[OncLive.com @OncLive]

WATCH 👀: @SaraNunneryMD, of @TNOncology, previews the latest episode of #BreastCancerBriefing, all about breast cancer data from #ESMO2026! @SPremji7866 @SarahCannonDocs @myESMO #bcsm

See the video on our site or listen across podcast platforms ➡️: https://t.co/qox5AwATy3

[OncLive.com @OncLive]

Thank you to @SaraNunneryMD, of @TNOncology, for sitting down with us at BTG Breast to talk about personalizing adjuvant endocrine therapy! #bcsm #oncology

See our site for more from the meeting ➡️: https://t.co/XonIlWO5yz

[OncLive.com @OncLive]

WATCH 🎥: @KelseyNatsuhara, of @UCSFCancer, discusses emerging ADCs and the importance of clinical trial enrollment in triple-negative breast cancer at the Bridging the Gaps in Breast Cancer meeting. #bcsm #oncology

Full video ➡️: https://t.co/GnxDIKTzrZ

[OncLive.com @OncLive]

💉 ICYMI: Intismeran autogene plus pembrolizumab improved RFS and DMFS in resected high-risk melanoma according to data from the ground breaking phase 3 INTerpath-001 trial at @myESMO

Read more here ➡️: https://t.co/QLGxK6UqnX

#melsm #oncology

[OncLive.com @OncLive]

With longer follow-up, the B7-H4–directed ADC Mo-Rez held a 62% confirmed ORR in platinum-resistant ovarian cancer, and median PFS reached 11.1 months at the dose now being tested in 5 phase 3 trials @myESMO #ESMO26 #gyncsm #ovca https://t.co/8xWA3mB8wL

[OncLive.com @OncLive]

⏳ Last chance to nominate!

Nominations for the 2027 Giants of Cancer Care® close this Sunday, November 15. Know an oncologist whose work has shaped the field? Nominate them today. https://t.co/lLRi9a0zYu #GiantsCC27

[OncLive.com @OncLive]

🧬 96% of evaluable tumors were B7-H4+, and responses to mocertatug rezetecan occurred across all B7-H4 expression levels in platinum-resistant ovarian cancer. New BEHOLD-1 biomarker data from #ESMO26 👇 #gyncsm #ovca @myESMO @StephanieLheur5 @PMResearch_UHN https://t.co/2nazgOmqx8

[OncLive.com @OncLive]

🎤 Crucial conversations are happening at the podium at BTG Breast! #bcsm #oncology

Check back on our site for exclusive expert insights ➡️: https://t.co/XonIlWODo7